BioSim™ anti-Rituximab (Mabthera®) (Human) ELISA Kit

Rituximab (Mabthera®) is a genetically engineered chimeric murine/human monoclonal antibody specific to CD20. CD20 is an approximately 35 KDa transmembrane phosphoprotein involved in the activation, proliferation, and differentiation of B-lymphocytes. It is absent in terminally differentiated plasma cells. The Fab domain of rituximab binds to the CD20 antigen on B-lymphocytes and the Fc domain recruits immune effector functions to induce apoptosis in B cells. It is used in treating leukemias and lymphomas, some autoimmune disorders, and organ transplant. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Rituximab ELISA kit is designed to quantify/measure the antibody against Rituximab with high specificity and sensitivity in biological matrices.

• Data sheet: View or download
• MSDS: View or download